Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.13% | -2.36% | -0.34% | 9.58% | 0.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.13% | -2.36% | -0.34% | 9.58% | 0.48% |
| Cost of Revenue | 7.28% | -6.13% | 6.32% | 11.54% | 6.11% |
| Gross Profit | -5.10% | -0.16% | -3.80% | 8.62% | -1.98% |
| SG&A Expenses | 2.27% | 1.02% | -2.10% | 3.08% | -4.17% |
| Depreciation & Amortization | 0.68% | -0.63% | -2.93% | 3.26% | -0.94% |
| Other Operating Expenses | -87.81% | 16.21% | 93.76% | -229.67% | 64.03% |
| Total Operating Expenses | -2.44% | 1.27% | 5.79% | -4.01% | 1.36% |
| Operating Income | 5.84% | -23.20% | -91.63% | 139.60% | -4.01% |
| Income Before Tax | 19.00% | -119.93% | -58.28% | 220.88% | -10.92% |
| Income Tax Expenses | -31.15% | 90.81% | 105.59% | 155.20% | -20.29% |
| Earnings from Continuing Operations | 40.74% | -3,254.14% | -78.19% | 286.62% | -6.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 23.81% | -131.29% | -27.20% | 1.18% | -308.49% |
| Net Income | 40.77% | -3,229.30% | -78.22% | 286.26% | -6.18% |
| EBIT | 5.84% | -23.20% | -91.63% | 139.60% | -4.01% |
| EBITDA | 3.90% | -16.69% | -27.32% | 50.52% | -2.67% |
| EPS Basic | 41.16% | -3,192.31% | -78.45% | 284.09% | -7.04% |
| Normalized Basic EPS | 2.92% | -29.64% | -222.14% | 263.60% | -0.70% |
| EPS Diluted | 40.82% | -3,192.31% | -78.45% | 281.08% | -7.59% |
| Normalized Diluted EPS | 2.69% | -29.64% | -222.14% | 257.55% | -1.29% |
| Average Basic Shares Outstanding | -0.27% | 0.84% | 1.04% | 1.17% | 0.93% |
| Average Diluted Shares Outstanding | -0.06% | 0.84% | 1.04% | 2.88% | 1.53% |
| Dividend Per Share | -- | 1.56% | -- | 1.32% | -- |
| Payout Ratio | -0.19% | 0.97% | 3.68% | 1.53% | -0.01% |